All In Biotech

Free tool

FAERS Monitor: Veozah

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 216578 or its brand name (Veozah, Fezolinetant). Reports on generic versions are filed under their own applications.

Reports

2,301

Serious

466

20% of reports

Hospitalization

88

Death reported

5

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective281
  • hepatic enzyme increased217
  • alanine aminotransferase increased200
  • aspartate aminotransferase increased153
  • headache130
  • off label use124
  • nausea110
  • hot flush107
  • liver function test increased98
  • insomnia94
  • diarrhoea86
  • fatigue84
  • abdominal pain72
  • dizziness67
  • back pain56

Reports by year received

View as table
YearReports
20201
20222
2023186
2024736
2025800
2026576

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,858 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
liver function test increasedSignal9841.934.53,859
alanine aminotransferase increasedSignal20029.926.25,550
hepatic enzyme increasedSignal21729.225.75,879
aspartate aminotransferase increasedSignal15326.422.73,713
hot flushSignal10713.010.81,175
insomniaSignal943.22.6144
abdominal painSignal722.82.384
back painSignal562.21.736
drug ineffective2811.91.7138
headache1301.91.656
off label use1241.31.18
nausea1101.31.16
dizziness671.21.03
diarrhoea861.21.03
fatigue841.00.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.